. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Am J Kidney Dis. 2018 Feb 23;72(5):728–744. doi: 10.1053/j.ajkd.2017.12.007

Table 4.

Randomized trials of lipid-lowering therapy for prevention of CV events in CKD

Study	Intervention	Comparator	Duration (y)	Sample (mean eGFR±SD)	Outcome
NDD-CKD
SHARP⁵⁹ (2011)	Simvastatin 20 mg/d + ezetimibe 10 mg/d	Placebo	5.0	6,247 NDD-CKD pts (26.6±12.9 vs. 26.6±13.1); 3,023 CKD-5D pts	Primary outcome (composite of MI, coronary death, non-hemorrhagic stroke, or arterial revascularization): RR, 0.78 (0.67-0.91) in NDD-CKD
CKD-5D
4D⁶⁰ (2005)	Atorvastatin 20 mg/d	Placebo	4.0	1,255 prevalent HD pts w/DM	Primary outcome (composite of CV death, MI, or stroke): RR, 0.92 (0.77-1.10)
AURORA⁶¹ (2009)	Rosuvastatin 10 mg/d	Placebo	5.0	2,776 prevalent HD pts	Primary outcome (composite of CV death, MI, or stroke): HR, 0.96
SHARP⁵⁹ (2011)	Simvastatin 20 mg/d + ezetimibe 10mg/d	Placebo	5.0	6,247 NDD-CKD pts; 3,023 CKD-5D pts (2,527 HD; 496 PD)	Primary outcome (composite of MI, coronary death, non-hemorrhagic stroke, or arterial revascularization): RRs of 0.90 (0.75-1.08) in CKD-5D, 0.95 (0.78-1.15) in HD, 0.70 (0.46-1.08) in PD

Abbreviations: 4D, Deutsche Diabetes Dialyse Studie; AURORA, Assessment of Survival and Cardiovascular Events; CKD-5D, dialysis-dependent chronic kidney disease; CV, cardiovascular; HD, hemodialysis; MI, myocardial infarction; NDD-CKD, non-dialysis-dependent chronic kidney disease; PD, peritoneal dialysis; RR, relative risk (values in parentheses are 95% confidence intervals); SD, standard deviation; SHARP, Study of Heart and Renal Protection; HR, hazard ratio.